CyteQuest — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CyteQuest is a private, pre-revenue platform technology company pioneering a next-generation microfluidic electroporation system for the cell and gene therapy (CGT) manufacturing sector. Its technology aims to overcome key bottlenecks in genetic modification—specifically the trade-off between transfection efficiency and cell viability—by applying a highly uniform electric field in a continuous flow format. With a strong founding team of experts in microfluidics and commercialization, the company is positioned to address the growing need for scalable, consistent, and gentle transfection solutions. CyteQuest's platform targets the acceleration and improvement of manufacturing processes for therapies like CAR-T, TCR, and gene-edited cell therapies.

DiagnosticsHematology

Technology Platform

Proprietary microfluidic electroporation platform for high-efficiency, high-viability transfection of genetic cargo into primary cells, utilizing a continuous flow system for scalable performance.

Opportunities

The rapid growth of the cell and gene therapy market creates a strong demand for scalable, efficient, and gentle manufacturing technologies.

CyteQuest's platform directly addresses key cost and yield bottlenecks, positioning it to capture share in the expanding market for non-viral transfection tools.

Partnerships with therapy developers and CDMOs for validation can lead to early adoption and potential strategic investment.

Risk Factors

The company faces significant competition from established, well-funded players in the electroporation market and must prove unequivocal performance advantages.

As a pre-revenue startup, it carries execution risk in transitioning from prototype to commercial product and depends on securing additional capital.

Adoption risk is high, as manufacturers may be reluctant to switch from validated, entrenched systems.

Competitive Landscape

CyteQuest competes in the electroporation and transfection market dominated by large players like Lonza (Nucleofector), MaxCyte (Flow Electroporation), and Bio-Rad. Its key differentiator is the combination of microfluidic continuous flow with a highly uniform electric field, aiming to surpass competitors on the critical balance of viability and efficiency. It also faces competition from newer viral and non-viral delivery technologies.

More companies in Drug Delivery & Formulation →More companies in United States →